Conference Description:

Whether it's in cardiovascular disease, Alzheimer's or osteoarthritis, therapeutic innovations to target the mechanisms of aging are making significant headway to clinical trials. With increased investments and recognition, along with the escalation of the burden of age-related disease, research and development to meet this unmet medical need has never been more important.The 5th Age-Related Disease Therapeutics Summit is the only industry-focused meeting dedicated to uniting 100+ biopharma drug developers, pioneering academics, and prominent investors striving to develop effective, novel drugs that promote healthy aging and overcome major translational and regulatory obstacles.

Jam-packed with the most cutting-edge insights and opportunities to reunite with and hear from your peers on the next steps forward in developing the safest and most efficacious drug to promote a healthier and enhanced quality of life.

URL:
Tickets: https://go.evvnt.com/1632255-2?pid=154
Time: 8:00 am - 4:00 pm

Prices:
Industry | Conference + 3 Workshops: USD 4946.00,
Industry | Conference + 2 Workshops: USD 4297.00,
Industry | Conference + 1 Workshop: USD 3648.00,
Industry | Conference Only: USD 2999.00,
Discounted | Conference + 3 Workshops: USD 4246.00,
Discounted | Conference + 2 Workshops: USD 3697.00,
Discounted | Conference + 1 Workshop: USD 3148.00,
Discounted | Conference Only: USD 2599.00,
Vendor | Conference + 3 Workshops: USD 6046.00,
Vendor | Conference + 2 Workshops: USD 5297.00

Speakers: Abdulkader Rahmo | Chief Scientific Officer and President | SMSbiotech, Alexander Pickett | Managing Director | Juvenescence, Andrei Gudkov | SVP | Roswell Park Cancer Center, Birgit Schilling | Professor and Director Proteomics Center | Buck Institute for Research on Aging, David Furman | Director and Professor | Buck Institute for Research on Aging, Doug Ethell | Chief Executive Officer and Founder | Leucadia Therapeutics, Eddie Moler | Vice President, Data Science | Juvena Therapeutics, Gayathri Swaminath | Senior Vice President, Discovery | Juvena Therapeutics, Hanadie Yousef | Chief Executive Officer and Co-Founder | Juvena Therapeutics, Hans Keirstead | Chief Executive Officer | Immunis, James Peyer | Chief Executive Officer | Cambrian Bio, Jerry McLaughlin | Chief Executive Officer | Life Biosciences, Jyothi Devakumar | Chief Scientific Officer and Partner | Longevitytech. fund, Kate Batz | Director of Strategy and Business Development | Deep Knowledge Ventures, Lorna Harries | Chief Scientific Officer | SENISCA, Louis Hawthorne | Chief Executive Officer | NaNotics, Marco Quarta | Chief Executive Officer and Co-Founder | Rubedo Life Sciences, Michael Fossel | President | Telocyte, Pankaj Kapahi | Professor | Buck Institute for Research on Aging, Peng Leong | Chief Business Officer and Head of Brain Aging | BioAge Labs, Reason | Chief Executive Officer and Co-Founder | Repair Biotechnologies, Robin Mansukhani | Chief Executive Officer and Co-Founder | Deciduous Therapeutics, Shamina Rangwala | Executive Director, Emerging Science, Innovation and Global Internal Medicine Lead | Pfizer, Szilard Voros | CEO/Founder | G3 Therapeutics and PUER, Viktoria Kheifets | Senior Vice President | Alkahest